Ionis Pharmaceuticals IONS Retained Earnings
Retained Earnings at other companies
Other financials
Where this comes from
Reported directly by Ionis Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:RetainedEarningsAccumulatedDeficit.
The official record: Ionis Pharmaceuticals’s 10-Q, filed April 29, 2026, on SEC EDGAR. View the filing →
Ask your AI about Ionis Pharmaceuticals's retained earnings.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Ionis Pharmaceuticals's retained earnings?
- Ionis Pharmaceuticals (IONS) reported retained earnings of -$2.72B in Q1 2026.
- How has Ionis Pharmaceuticals's retained earnings changed year-over-year?
- Ionis Pharmaceuticals's retained earnings decreased by 13.6% year-over-year, from -$2.4B to -$2.72B.
- What is the long-term trend for Ionis Pharmaceuticals's retained earnings?
- Over 5 years (2020 to 2025), Ionis Pharmaceuticals's retained earnings has grown at a 18.4% compound annual growth rate (CAGR), from -$1.13B to -$2.63B.
- What does retained earnings mean?
- The total profits the company has kept and reinvested since it started.
- How do you interpret retained earnings?
- A growing balance indicates consistent profitability and internal funding capacity, while a negative balance (accumulated deficit) is common for early-stage biotech firms.
- How does retained earnings compare across companies?
- Varies widely between mature profitable firms and growth-stage biotech companies.